WHAT IS CLAIMED IS:

1. A compound represented by Formula I:



I

or a pharmaceutically acceptable salt or solvate thereof, wherein:

A and B may be taken separately or together;

when taken separately,

A represents halo, C_{1-6}alkyl, OC_{1-6}alkyl or phenyl, said alkyl, phenyl and the alkyl portion of OC_{1-6}alkyl being optionally substituted with 1-3 halo groups; and

B represents represents H, halo, C_{1-6}alkyl, -OC_{1-6}alkyl, -SC_{1-6}alkyl, C_{2-6}alkenyl, phenyl or naphthyl, said alkyl, alkenyl, phenyl, naphthyl, and the alkyl portions of -OC_{1-6}alkyl and -SC_{1-6}alkyl being optionally substituted with 1-3 groups selected from halo, OH, CH_3O, CF_3 and OCF_3; and

when taken together,

A and B together represents (a) C_{1-4}alkylene optionally substituted with 1-3 halo groups, and 1-2 R^a groups wherein R^a represents C_{1-3}alkyl, OC_{1-3}alkyl, $C_{6-10}arC_{1-6}$alkylene or phenyl optionally substituted with 1-3 halo groups, or (b) C_{2-5}alkanediyl such that they form a 3-6 membered ring with the carbon atom to which they are attached, said ring optionally containing 1 double bond or 1-2 heteroatoms selected from O, S and N, said 3-6 membered ring being optionally substituted with C_{1-4}alkylene, oxo, ethylenedioxy or propylenedioxy, and being further optionally substituted with 1-4 groups selected from halo, C_{1-4}alkyl, haloC_{1-4}alkyl, C_{1-3}acyl, C_{1-3}acyloxy, C_{1-3}alkoxy, C_{1-6}alkylOC(O)-, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-3}alkoxyC_{1-3}alkyl, C_{1-3}alkoxyC_{1-3}alkoxy, phenyl, CN, OH, D, NH_2, NHR^a and $N(R^a)_2$ wherein R^a is as previously defined;

each R^1 represents H or is independently selected from the group consisting of: OH, halo, C_{1-10}alkyl, C_{1-6}alkoxy and C_{6-10}aryl, said C_{1-10}alkyl, C_{6-10}aryl and the alkyl portion of C_{1-6}alkoxy being optionally substituted with 1-3 halo, OH, OC_{1-3}alkyl, phenyl or naphthyl groups, said phenyl and naphthyl being optionally substituted with 1-3 substituents independently selected from halo, OCH_3, OCF_3, CH_3, CF_3 and phenyl, wherein said phenyl is optionally substituted with 1-3 halo groups,

or two R^1 groups taken together represent a fused C_{5-6}alkyl or aryl ring, which may be optionally substituted with 1-2 OH or R^a groups, wherein R^a is as defined above;

R^2 and R^3 are taken together or separately;

when taken together, R^2 and R^3 represent (a) a C_{3-8} alkanediyl forming a fused 5-10 membered non-aromatic ring optionally interrupted with 1-2 double bonds, and optionally containing 1-2 heteroatoms selected from O, S and N; or (b) a fused 6-10 membered aromatic monocyclic or bicyclic group, said alkanediyl and aromatic monocyclic or bicyclic group being optionally substituted with 1-6 halo atoms, and 1-4 of OH, C_{1-3}alkyl, OC_{1-3}alkyl, haloC_{1-3}alkyl, haloC_{1-3}alkoxy, and phenyl, said phenyl being optionally substituted with 1-4 groups independently selected from halo, C_{1-3}alkyl, OC_{1-3}alkyl , and said C_{1-3}alkyl and the C_{1-3}alkyl portion of OC_{1-3}alkyl being optionally substituted with 1-3 halo groups;

when taken separately,

R^2 is selected from the group consisting of: (a) C_{1-14}alkyl optionally substituted with 1-6 halo groups and 1-3 substituents selected from OH, OC_{1-3}alkyl, and phenyl, said phenyl being optionally substituted with 1-4 groups independently selected from halo, OCH_3, OCF_3, CH_3 and CF_3, and said C_{1-3}alkyl portion of OC_{1-3}alkyl being optionally substituted with 1-3 halo groups; (b) phenyl or pyridyl optionally substituted with 1-3 halo, OH or R^a groups, with R^a as previously defined; (c) C_{2-10} alkenyl, optionally substituted with 1-3 substituents independently selected from halo, OH and OC_{1-3}alkyl, said C_{1-3}alkyl portion of OC_{1-3}alkyl being optionally substituted with 1-3 halo groups; (d) CH_2CO_2H; (e) $CH_2CO_2C_{1-6}$alkyl; (f) $CH_2C(O)NHR^a$ wherein R^a is as previously defined; (g) NH_2, NHR^a and $N(R^a)_2$ wherein R^a is as previously defined;

and R^3 is selected from the group consisting of: C_{1-14}alkyl, C_{2-10}alkenyl, SC_{1-6}alkyl, C_{6-10}aryl, heterocyclyl and heteroaryl, said alkyl, alkenyl, aryl, heterocyclyl, heteroaryl and the alkyl portion of SC_{1-6}alkyl being optionally substituted with (a) R; (b) 1-6 halo groups and (c) 1-3 groups selected from OH, NH_2, NHC_{1-4}alkyl, $N(C_{1-4}alkyl)_2$, C_{1-4}alkyl, OC_{1-4}alkyl, CN, $C_{1-4}alkylS(O)_x$- wherein x is 0, 1 or 2, $C_{1-4}alkylSO_2NH$-, H_2NSO_2-, $C_{1-4}alkylNHSO_2$- and $(C_{1-4}alkyl)_2NSO_2$-, said C_{1-4}alkyl and the C_{1-4}alkyl portions of said groups being optionally substituted with phenyl and 1-3 halo groups, and

R is selected from heterocyclyl, heteroaryl and aryl, said group being optionally substituted with 1-4 groups selected from halo, C_{1-4}alkyl, $C_{1-4}alkylS(O)_x$-, with x as previously defined, C_{1-4} alkylSO_2NH-, H_2NSO_2-, $C_{1-4}alkylNHSO_2$-, $(C_{1-4}$ alkyl$)_2NSO_2$-, CN, OH, OC_{1-4}alkyl , and, said C_{1-4}alkyl and the C_{1-4}alkyl portions of said groups being optionally substituted with 1-5 halo and 1 group selected from OH and OC_{1-3}alkyl.

2. The compound of Claim 1 wherein A and B are taken separately and each represents a C_{1-6}alkyl group, optionally substituted with 1-3 halo groups.

3. The compound of Claim 1 wherein A and B are taken together and represent C_{2-5}alkanediyl such that a 3-6 membered ring is formed with the carbon atom to which they are attached, said ring optionally containing 1 double bond or 1-2 heteroatoms selected from O, S and N, said 3-6 membered ring being optionally substituted with C_{1-4}alkylene, oxo, ethylenedioxy or propylenedioxy, and being further optionally substituted with 1-4 groups selected from halo, C_{1-4}alkyl, haloC_{1-4}alkyl, C_{1-3}acyl, C_{1-3}acyloxy, C_{1-3}alkoxy, C_{1-6}alkylOC(O)-, C_{2-4}alkenyl, C_{2-4}alkynyl, $C_{1-3}alkoxyC_{1-3}$alkyl, $C_{1-3}alkoxyC_{1-3}$alkoxy, phenyl, CN, OH, D, NH_2, NHR^a and $N(R^a)_2$ wherein R^a represents C_{1-3}alkyl, OC_{1-3}alkyl, $C_{6-10}arC_{1-6}$alkylene or phenyl optionally substituted with 1-3 halo groups.

4. The compound of Claim 3 wherein A and B are taken together and represent a C_{2-4} membered alkanediyl group such that a 3 to 5 membered ring is formed with the carbon atom to which they are attached, optionally substituted with 1-

2 groups selected from halo, C_{1-4}alkyl, haloC_{1-4}alkyl, C_{1-3}alkoxy, C_{1-3}alkoxyC_{1-3}alkyl, C_{1-3}alkoxyC_{1-3}alkoxy and phenyl.

5. The compound of Claim 4 wherein A and B are taken together and represent a C_{2-4} alkanediyl group such that a 3-5 membered ring is formed with the carbon atom to which they are attached, said ring being unsubstituted or substituted with 1-2 halo groups.

6. The compound of Claim 5 wherein the 1-2 halo groups are fluoro groups.

7. The compound of Claim 1 wherein two R^1 groups represent H and one R^1 is selected from the group consisting of: OH, halo, C_{1-10}alkyl, C_{1-6}alkoxy and C_{6-10}aryl, said C_{1-10}alkyl, C_{6-10}aryl and the alkyl portion of C_{1-6}alkoxy being optionally substituted with 1-3 halo, OH, OC_{1-3}alkyl, phenyl or naphthyl groups, said phenyl and naphthyl being optionally substituted with 1-3 substituents selected from: halo, OCH_3, OCF_3, CH_3, CF_3 and phenyl, wherein said phenyl is optionally substituted with 1-3 halo groups.

8. The compound of Claim 1 wherein one R^1 group represents H and two R^1groups are selected from the group consisting of: OH, halo, C_{1-10}alkyl and C_{1-6}alkoxy, said C_{1-10}alkyl and the alkyl portion of C_{1-6}alkoxy being optionally substituted with 1-3 halo groups.

9. The compound of Claim 8 wherein two R^1 groups represent halo or methyl.

10. The compound of Claim 1 wherein R^2 is taken separately from R^3 and is selected from the group consisting of: (a) C_{1-14}alkyl optionally substituted with 1-6 halo groups and 1-3 substituents selected from OH, OC_{1-3}alkyl, and phenyl, said phenyl being optionally substituted with 1-4 groups independently selected from

halo, OCH_3, OCF_3, CH_3 and CF_3, and said C_{1-3}alkyl portion of OC_{1-3}alkyl being optionally substituted with 1-3 halo groups; (b) phenyl or pyridyl optionally substituted with 1-3 halo, OH or R^a groups; (c) C_{2-10} alkenyl, optionally substituted with 1-3 substituents independently selected from halo, OH and OC_{1-3}alkyl, said C_{1-3}alkyl portion of OC_{1-3}alkyl being optionally substituted with 1-3 halo groups; (d) CH_2CO_2H; (e) $CH_2CO_2C_{1-6}$alkyl; (f) $CH_2C(O)NHR^a$ and (g) NH_2, NHR^a and $N(R^a)_2$, and

R^a represents C_{1-3}alkyl, OC_{1-3}alkyl, $C_{6-10}arC_{1-6}$alkylene or phenyl optionally substituted with 1-3 halo groups.

11. The compound of Claim 1 wherein R^2 is taken separately from R^3 and is C_{1-14}alkyl optionally substituted with 1-6 halo groups and 1-3 substituents selected from OH, OC_{1-3}alkyl and phenyl, said phenyl being optionally substituted with 1-4 groups independently selected from halo, OCH_3, OCF_3, CH_3 and CF_3, and the alkyl portion of OC_{1-3}alkyl being optionally substituted with 1-3 halo groups.

12. The compound of Claim 10 wherein R^2 is taken separately from R^3 and represents methyl or cyclopropyl.

13. The compound of Claim 1 wherein R^3 is taken separately from R^2 and is selected from the group consisting of: C_{1-14}alkyl, C_{2-10}alkenyl, SC_{1-6}alkyl, C_{6-10}aryl, heterocyclyl and heteroaryl, said alkyl, alkenyl, aryl, heterocyclyl, heteroaryl and the alkyl portion of SC_{1-6}alkyl being optionally substituted with (a) R; (b) 1-6 halo groups and (c) 1-3 groups selected from OH, NH_2, NHC_{1-4}alkyl, $N(C_{1-4}alkyl)_2$, C_{1-4}alkyl, OC_{1-4}alkyl, CN, $C_{1-4}alkylS(O)_x$- wherein x is 0, 1 or 2, $C_{1-4}alkylSO_2NH$-, H_2NSO_2-, $C_{1-4}alkylNHSO_2$- and $(C_{1-4}alkyl)_2NSO_2$-, said C_{1-4}alkyl and the C_{1-4}alkyl portions of said groups being optionally substituted with phenyl and 1-3 halo groups, and

R is selected from heterocyclyl, heteroaryl and aryl, said group being optionally substituted with 1-4 groups selected from halo, C_{1-4}alkyl, $C_{1-4}alkylS(O)_x$-, with x as previously defined, C_{1-4} $alkylSO_2NH$-, H_2NSO_2-, $C_{1-4}alkylNHSO_2$-, $(C_{1-4}$ $alkyl)_2NSO_2$-, CN, OH, OC_{1-4}alkyl , and, said C_{1-4}alkyl and the C_{1-4}alkyl portions

of said groups being optionally substituted with 1-5 halo and 1 group selected from OH and OC_{1-3}alkyl.

14. The compound of Claim 13 wherein R^3 is taken separately from R^2 and is selected from the group consisting of: C_{1-14}alkyl, C_{6-10}aryl, heterocyclyl and heteroaryl, said groups being optionally substituted with (a) R; (b) 1-6 halo groups and (c) 1-3 groups selected from OH, NH_2, NHC_{1-4}alkyl, $N(C_{1-4}alkyl)_2$, C_{1-4}alkyl, OC_{1-4}alkyl, CN, $C_{1-4}alkylS(O)_x$- wherein x is 0, 1 or 2, $C_{1-4}alkylSO_2NH$-, H_2NSO_2-, $C_{1-4}alkylNHSO_2$-, $(C_{1-4}alkyl)_2NSO_2$-, said C_{1-4}alkyl and the C_{1-4}alkyl portions of said groups being optionally substituted with phenyl and 1-3 halo groups.

15. The compound of Claim 13 wherein R^3 is taken separately and is selected from the group consisting of: cyclopropyl optionally substituted with methyl or phenyl; phenyl optionally substituted with halo, OH, OCH_3 or OCF_3; heteroaryl selected from benzimidazolyl, indolyl, benzofuranyl, and dihydrobenzofuranyl, said heteroaryl groups being optionally substituted with: (a) R; (b) 1-6 halo groups or (c) 1-3 groups selected from OH, NH_2, NHC_{1-4}alkyl, $N(C_{1-4}alkyl)_2$, C_{1-4}alkyl, OC_{1-4}alkyl, CN, $C_{1-4}alkylS(O)_x$- wherein x is 0, 1 or 2, $C_{1-4}alkylSO_2NH$-, H_2NSO_2-, $C_{1-4}alkylNHSO_2$-, $(C_{1-4}alkyl)_2NSO_2$-, said C_{1-4}alkyl and the C_{1-4}alkyl portions of said groups being optionally substituted with phenyl and 1-3 halo groups, and

R is selected from heterocyclyl, heteroaryl and aryl, said group being optionally substituted with 1-4 groups selected from halo, C_{1-4}alkyl, OH, OC_{1-4}alkyl, and, said C_{1-4}alkyl and the C_{1-4}alkyl portions of said groups being optionally substituted with 1-5 halo groups and 1 group selected from OH and OC_{1-3}alkyl.

16. The compound of Claim 1 wherein R^2 and R^3 are taken together and represent: (a) a C_{3-8} alkanediyl forming a fused 5-10 membered non-aromatic ring optionally interrupted with 1 double bond, and optionally interrupted by 1 heteroatom selected from O, S and N; or (b) a fused 6-10 membered aromatic monocyclic or bicyclic group,

said alkanediyl and aromatic monocyclic or bicyclic group being optionally substituted with 1-3 halo atoms, and 1-2 of OH, C_{1-3}alkyl, OC_{1-3}alkyl, haloC_{1-3}alkyl, haloC_{1-3}alkoxy and phenyl, said phenyl being optionally substituted with 1-2 groups independently selected from halo, C_{1-3}alkyl, OC_{1-3}alkyl , and said C_{1-3}alkyl and the C_{1-3}alkyl portion of OC_{1-3}alkyl being optionally substituted with 1-3 halo groups.

17. The compound of Claim 1 wherein R is selected from heterocyclyl, heteroaryl and aryl, said group being optionally substituted with 1-4 halo groups and 1-2 groups selected from C_{1-4}alkyl, C_{1-4}alkyl$S(O)_x$-, wherein x is 0, 1 or 2, C_{1-4} alkylSO_2NH-, H_2NSO_2-, C_{1-4}alkyl$NHSO_2$-, $(C_{1-4}$ alkyl$)_2NSO_2$-, CN, OH and OC_{1-4}alkyl, said C_{1-4}alkyl and the C_{1-4}alkyl portions of said groups being optionally substituted with 1-3 halo groups and 1 group selected from OH and OC_{1-3}alkyl.

18. The compound of Claim 1 selected from the table set forth below:

Cpd	Structure	Cpd	Structure
1-1		2-1	
1-2		2-2	

1-3		2-3	
1-4		2-4	
1-5		2-5	
1-6		2-6	

1-7		2-7	
1-8		2-8	
1-9		2-9	
1-10		2-10	

1-11		2-11	
1-12		2-12	
1-13		2-13	
1-14		2-14	

1-15		2-15	
1-16		2-16	
2-17		2-51	
2-18		2-52	

2-19		3-1	
2-20		3-2	
2-21		3-3	
2-22		3-4	

2-23		3-5	
2-24		3-6	
2-25		3-7	
2-26		3-8	

2-27		3-9	
2-28		3-10	
2-29		3-11	
2-30		3-12	

2-31		3-13	
2-32		3-14	
2-33		3-15	
2-49		3-16	
2-50		3-17	

3-18		3-28	
3-19		3-29	
3-20		3-41	
3-21		3-42	
3-22		4-1	

3-24		4-2	
3-25		4-3	
3-26		4-4	
3-27		4-5	
3-30		4-6	

3-31		4-7	
3-32		3-23	
3-33		4-8	
3-34		4-9	
3-35		4-10	

3-36		4-11	
3-37		4-12	
3-38		4-13	
3-39		4-14	

3-40		4-15	
2-34		2-35	
2-36		2-37	
2-38		2-39	

2-40		2-41	
2-42		2-43	
2-44		2-45	
2-46		2-47	

2-48	

or a pharmaceutically acceptable salt or solvate thereof.

19. The compound of Claim 1 selected from the table below:

Cpd	Structure	Cpd	Structure
2-11		2-13	
2-19		3-1	
2-21		3-2	

3-3		3-4	
3-5		3-6	
3-7		3-9	

2-26		3-8	
2-29		3-10	
2-30		3-11	
3-14		3-12	
3-15		3-13	

2-49		3-16	
2-50		3-17	
3-18		3-28	
3-19		3-29	
3-20		3-41	

3-21		3-42	
3-22		4-1	
3-24		4-2	
3-25		4-3	
3-26		4-4	

3-27		4-5	
3-30		4-6	
3-31		4-7	
3-32		4-8	
3-33		4-9	

3-34		4-10	
3-35		4-11	
3-36		4-12	
3-37		4-13	
3-38		4-14	

3-39		4-15	
3-40			

or a pharmaceutically acceptable salt or solvate thereof.

20. A compound selected from the group consisting of:









5







and



or a pharmaceutically acceptable salt or solvate thereof.

21. The compound of Claim 20 of the structural formula:



or a pharmaceutically acceptable salt or solvate thereof.

22. The compound of Claim 20 of the structural formula:



or a pharmaceutically acceptable salt or solvate thereof.

23. The compound of Claim 20 of the structural formula:



or a pharmaceutically acceptable salt or solvate thereof.

24. The compound of Claim 20 of the structural formula:



or a pharmaceutically acceptable salt or solvate thereof.

25. A pharmaceutical composition comprising a compound in accordance with Claim 1 in combination with a pharmaceutically acceptable carrier.

26. A method of treating hyperglycemia, diabetes or insulin resistance in a mammalian patient in need of such treatment which comprises

administering to said patient an effective amount of a compound in accordance with Claim 1.

27. A method of treating non-insulin dependent diabetes mellitus in a mammalian patient in need of such treatment comprising administering to the patient an anti-diabetic effective amount of a compound in accordance with Claim 1.

28. A method of treating obesity in a mammalian patient in need of such treatment compriseing administering to said patient a compound in accordance with Claim 1 in an amount that is effective to treat obesity.

29. A method of treating Syndrome X in a mammalian patient in need of such treatment, comprising administering to said patient a compound in accordance with Claim 1 in an amount that is effective to treat Syndrome X.

30. A method of treating a lipid disorder selected from the group conisting of dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL and high LDL in a mammalian patient in need of such treatment, comprising administering to said patient a compound in accordance with Claim 1 in an amount that is effective to treat said lipid disorder.

31. A method of treating atherosclerosis in a mammalian patient in need of such treatment, comprising administering to said patient a compound in accordance with Claim 1 in an amount effective to treat atherosclerosis.

32. A method of treating a condition selected from the group consisting of: (1) hyperglycemia, (2) low glucose tolerance, (3) insulin resistance, (4) obesity, (5) lipid disorders, (6) dyslipidemia, (7) hyperlipidemia, (8) hypertriglyceridemia, (9) hypercholesterolemia, (10) low HDL levels, (11) high LDL levels, (12) atherosclerosis and its sequelae, (13) vascular restenosis, (14) pancreatitis, (15) abdominal obesity, (16) neurodegenerative disease, (17) retinopathy, (18) nephropathy, (19) neuropathy, (20) Syndrome X, and other conditions and disorders where insulin resistance is a component, in a mammalina

patient in need of such treatment, comprising administering to the patient a compound in accordance with Claim 1 in an amount that is effective to treat said condition.

33. A method of delaying the onset of a condition selected from the group consisting of (1) hyperglycemia, (2) low glucose tolerance, (3) insulin resistance, (4) obesity, (5) lipid disorders, (6) dyslipidemia, (7) hyperlipidemia, (8) hypertriglyceridemia, (9) hypercholesterolemia, (10) low HDL levels, (11) high LDL levels, (12) atherosclerosis and its sequelae, (13) vascular restenosis, (14) pancreatitis, (15) abdominal obesity, (16) neurodegenerative disease, (17) retinopathy, (18) nephropathy, (19) neuropathy, (20) Syndrome X, and other conditions and disorders where insulin resistance is a component in a mammalina patient in need of such treatment, comprising administering to the patient a compound in accordance with Claim 1 in an amount that is effective to delay the onset of said condition.

34. A method of reducing the risk of developing a condition selected from the group consisting of (1) hyperglycemia, (2) low glucose tolerance, (3) insulin resistance, (4) obesity, (5) lipid disorders, (6) dyslipidemia, (7) hyperlipidemia, (8) hypertriglyceridemia, (9) hypercholesterolemia, (10) low HDL levels, (11) high LDL levels, (12) atherosclerosis and its sequelae, (13) vascular restenosis, (14) pancreatitis, (15) abdominal obesity, (16) neurodegenerative disease, (17) retinopathy, (18) nephropathy, (19) neuropathy, (20) Syndrome X, and other conditions and disorders where insulin resistance is a component in a mammalian patient in need of such treatment, comprising administering to the patient a compound in accordance with Claim 1 in an amount that is effective to reduce the risk of developing said condition.

35. A method of treating a condition selected from the group consisting of (1) hyperglycemia, (2) low glucose tolerance, (3) insulin resistance, (4) obesity, (5) lipid disorders, (6) dyslipidemia, (7) hyperlipidemia, (8) hypertriglyceridemia, (9) hypercholesterolemia, (10) low HDL levels, (11) high LDL levels, (12) atherosclerosis and its sequelae, (13) vascular restenosis, (14) pancreatitis, (15) abdominal obesity, (16) neurodegenerative disease, (17) retinopathy, (18) nephropathy, (19) neuropathy, (20) Syndrome X, and other conditions and disorders where insulin resistance is a component, in a mammalian

patient in need of such treatment, comprising administering to the patient an effective amount of a compound as defined in Claim 1, and a compound selected from the group consisting of:

(a) DP-IV inhibitors;

(b) insulin sensitizers selected from the group consisting of (i) PPAR agonists and (ii) biguanides;

(c) insulin and insulin mimetics;

(d) sulfonylureas and other insulin secretagogues;

(e) α-glucosidase inhibitors;

(f) glucagon receptor antagonists;

(g) GLP-1, GLP-1 mimetics, and GLP-1 receptor agonists;

(h) GIP,GIP mimetics, and GIP receptor agonists;

(i) PACAP, PACAP mimetics, and PACAP receptor 3 agonists;

(j) cholesterol lowering agents selected from the group consisting of (i) HMG-CoA reductase inhibitors, (ii) sequestrants, (iii) nicotinyl alcohol, nicotinic acid and salts thereof, (iv) PPARα agonists, (v) PPARα/γ dual agonists, (vi) inhibitors of cholesterol absorption, (vii) acyl CoA:cholesterol acyltransferase inhibitors, and (viii) anti-oxidants;

(k) PPARδ agonists;

(l) antiobesity compounds;

(m) an ileal bile acid transporter inhibitor

(n) anti-inflammatory agents excluding glucocorticoids; and

(o) protein tyrosine phosphatase-1B (PTP-1B) inhibitors,

said compounds being administered to the patient in an amount that is effective to treat said condition.

36. A method of treating a condition selected from the group consisting of hypercholesterolemia, atherosclerosis, low HDL levels, high LDL levels, hyperlipidemia, hypertriglyceridemia and dyslipidemia, in a mammalina patient in need of such treatment, comprising administering to the patient a therapeutically effective amount of a compound as defined in Claim 1 and an HMG-CoA reductase inhibitor.

37. The method of Claim 36 wherein the HMG-CoA reductase inhibitor is a statin.

38. The method of Claim 37 wherein the statin is selected from the group consisting of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, itavastatin, ZD-4522 and rivastatin.

39. A method of reducing the risk of developing a condition selected from the group consisting of hypercholesterolemia, atherosclerosis, low HDL levels, high LDL levels, hyperlipidemia, hypertriglyceridemia and dyslipidemia, and the sequelae of such conditions comprising administering to a mammalian patient in need of such treatment a therapeutically effective amount of a compound as defined in Claim 1 and an HMG-CoA reductase inhibitor.

40. A method for delaying the onset or reducing the risk of developing atherosclerosis in a human patient in need of such treatment comprising administering to said patient an effective amount of a compound as defined in Claim 1, and an HMG-CoA reductase inhibitor.

41. The method of Claim 39 wherein the HMG-CoA reductase inhibitor is a statin.

42. A method of Claim 41 wherein the statin is selected from the group consisting of: lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, itavastatin, ZD-4522 and rivastatin.

43. The method of Claim 42 wherein the statin is simvastatin.

44. The method of Claim 43 further comprising administering a cholesterol absorption inhibitor.

45. The method of Claim 44 wherein the cholesterol absorption inhibitor is ezetimibe.

46. A pharmaceutical composition comprising

(1) a compound according to Claim 1,

(2) a compound selected from the group consisting of :

(a) DP-IV inhibitors;

(b) insulin sensitizers selected from the group consisting of (i) PPAR agonists and (ii) biguanides;

(c) insulin and insulin mimetics;

(d) sulfonylureas and other insulin secretagogues;

(e) α-glucosidase inhibitors;

(f) glucagon receptor antagonists;

(g) GLP-1, GLP-1 mimetics, and GLP-1 receptor agonists;

(h) GIP, GIP mimetics, and GIP receptor agonists;

(i) PACAP, PACAP mimetics, and PACAP receptor 3 agonists;

(j) cholesterol lowering agents selected from the group consisting of (i) HMG-CoA reductase inhibitors, (ii) sequestrants, (iii) nicotinyl alcohol, nicotinic acid or a salt thereof, (iv) PPARα agonists, (v) PPARα/γ dual agonists, (vi) inhibitors of cholesterol absorption, (vii) acyl CoA:cholesterol acyltransferase inhibitors, and (viii) anti-oxidants;

(k) PPARδ agonists;

(l) antiobesity compounds;

(m) an ileal bile acid transporter inhibitor;

(n) anti-inflammatory agents other than glucocorticoids; and

(o) protein tyrosine phosphatase-1B (PTP-1B) inhibitors; and

(3) a pharmaceutically acceptable carrier.